Exhaled nitric oxide is increased in active fibrosing alveolitis

Chest

Volumn 115, Issue 5, 1999, Pages 1352-1356

  Paredi, Paolo ^a   Kharitonov, S A ^a   Loukides, S ^a   Pantelidis, P ^b   Du Bois, R M ^b   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Fibrosing alveolitis; Inflammation; Nitric oxide

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PENICILLAMINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHIECTASIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCLERODERMA;

EID: 0032894821     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.5.1352     Document Type: Article

References (28)

1. 1 Gauldie J, Jordana M, Cox G. Cytokines and pulmonary flbrosis. Thorax 1993; 48:931-935
2. 2 Strausz J, Muller-Quernheim J, Steppling H, et al. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary flbrosis. Am Rev Respir Dis 1993; 141:124-128
3. 3 Saleh D, Barnes PJ, Giaid A. Increased production of potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary flbrosis. Am J Respir Crit Care Med 1997; 155: 1763-1769
4. 4 Fukuo K, Inoue T, Morimoto S, et al. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. J Clin Invest 1995; 95:669-676
5. 5 Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992; 298:446-451
6. 6 Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144:706-713
7. 7 Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801-809
8. 8 Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic alveolitis. Am Respir Crit Care Med 1994; 149:1583-1590
9. 9 Barnes PJ. Nitric oxide and airways. Eur Respir J 1993; 6:163-165
10. 10 Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993; 6:1368-1370
11. 11 Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343:133-135
12. 12 Kharitonov SA, Wells AU, O'Connor BJ, et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151:1889-1893
13. 13 Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269:13725-13728
14. 14 Wells AU, Hansell DM, Rubens MB, et al. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis. Am J Respir Crit Care Med 1997; 155:1657-1664
15. 15 Mathieson JR, Mayo JR, Staples CA, et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989; 171:111-116
16. 16 Tung KT, Wells AC, Rubens MB, et al. Accuracy of typical computed tomography appearances of fibrosing alveolitis. Thorax 1993; 48:334-338
17. 17 Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-590
18. 18 Kharitonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir J 1997; 7:1683-1693
19. 19 Behr J, Vigelmeir C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154:400-406
20. 20 Halsam PL, Turton CW, Heard B, et al. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35:9-18
21. 21 Kharitonov SA, Chung KF, Evans DJ, et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996; 153:1773-1780
22. 22 Kovacs EJ, Di Pietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994; 8:854-861
23. 23 Mornex JF, Leroux T, Greenland T, et al. From granuloma to fibrosis in interstitial lung disease: molecular and cellular interactions. Eur Respir J 1994; 7:779-785
24. 24 Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254:1001-1003
25. 25 Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly [review]. Am J Physiol 1996; 271:C1424-C1437
26. 26 Southcott AM, Jones KP, Li D, et al. Interleukin-8 differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995; 151:1604-1612
27. 27 Haslam PL, Turton CW, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328-339.
28. 28 Kharitonov SA, Cailes JB, Black CM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52:1051-1055.